The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United…
Tyvaso boosts lung function in IPF trial, per top-line data
First in a series. Shortly after I learned I had idiopathic pulmonary fibrosis (IPF) in January 2017, I came to rely on the Pulmonary Fibrosis Foundation (PFF) as a reliable source of information. That relationship continues today, more than four years after my bilateral lung transplant in…
September is Pulmonary Fibrosis Awareness Month, and organizations around the world are gearing up to educate others and bring attention to pulmonary fibrosis (PF) — and also interstitial lung diseases (ILDs), which are disorders marked by scarring in the lungs. “We urgently need broader awareness because with it…
“Anticipation, anticipation/ Is makin’ me late/ Is keepin’ me waitin’.” The chorus of Carly Simon’s 1971 song “Anticipation” came to mind earlier this week as my wife, Susan, and I prepare to leave for vacation. Despite booking our trip through the Czech Republic, Germany, and France almost a year…
Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving approval from the country’s Medicines and Healthcare Products Regulatory Agency (MHRA). “This MHRA approval marks an important…
My recent pulmonary function test (PFT) results indicated a decline in all the areas it measured. That’s not unusual for me. In the spring, my PFT numbers had declined, as well, leading to a diagnosis of pneumonia that was treated with antibiotics. This time a CT scan was ordered.
Consistently tracking the levels of Krebs von den Lungen-6 (KL-6), a protein that can indicate lung inflammation or damage, may help predict acute exacerbations in people with idiopathic pulmonary fibrosis (IPF) and other types of fibrotic interstitial lung diseases (ILDs), a study reports. Findings indicated that KL-6 levels tended…
When your time here on Earth is done, what will your legacy be? We all leave one behind, intentionally or unintentionally. What do you want to be remembered for? When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I’d already retired once from a successful…
Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis of biomarker data from an ongoing Phase 2a clinical trial. “These 6-week interim biomarker data, while early and based on…
During my journey with idiopathic pulmonary fibrosis, I’ve noticed periods of silence that affect not only patients, but also caregivers. I experienced my first significant such period about eight months after my diagnosis in January 2017. I took disability leave from my job as I was no longer able…
